Category: Sandoz
-
Cross-border injunctions “have their place” but can be “big ask”: Sandoz Global Head of IP Julia Pike
There is a place for cross-border injunctions, but in more nuanced cases (such as Regeneron v. Advanz) it’s a “big ask” for one country to take that decision itself on behalf of all those other countries, the company’s Global Head of IP Julia Pike has told ip fray.
-
Bayer Xarelto cases: Denmark becomes interesting patent PI jurisdiction after first Supreme Court clarification of strong validity presumption
The top Danish court also spoke out on the impact of redundant patent claim elements.
-
10x Genomics, Moderna, Novo Nordisk among newly confirmed speakers for Patent Litigation Europe event (pharma & tech) next month
Eric Whitaker, Chief Legal Officer at 10x Genomics, Karen Guo, Senior Director of Patents & IP at Novo Nordisk, and Katherine Hinterberg, Senior Director of Patent Litigation at Moderna, will speak at Kisaco Research’s annual Pharma and Biotech Patent Litigation Europe in Amsterdam.
-
Doctrine of equivalents removes painkiller from German market: GrĂĽnenthal wins preliminary injunction on appeal
A pharma patent and unfair competition dispute has taken a remarkable turn as the Dusseldorf Higher Regional Court granted a preliminary injunction based on infringement by equivalents.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.
-
UK wrongful-enforcement damages standard at issue in Sandoz v. Bayer; disclosures in South African patent lawsuits can influence parallel cases
Sandoz is seeking a disgorgement of profits from Bayer, alleging that misrepresentations to the European Patent Office are a basis for going beyond the usual compensation.